These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28867275)

  • 1. Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?
    Maan R; Feld JJ
    Gastroenterology; 2017 Oct; 153(4):890-892. PubMed ID: 28867275
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
    Virlogeux V; Pradat P; Hartig-Lavie K; Bailly F; Maynard M; Ouziel G; Poinsot D; Lebossé F; Ecochard M; Radenne S; Benmakhlouf S; Koffi J; Lack P; Scholtes C; Uhres AC; Ducerf C; Mabrut JY; Rode A; Levrero M; Combet C; Merle P; Zoulim F
    Liver Int; 2017 Aug; 37(8):1122-1127. PubMed ID: 28423231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: hepatocellular carcinoma risk in the era of direct-acting anti-virals-is the case closed?
    Tan PS; Lim SG
    Aliment Pharmacol Ther; 2018 Jan; 47(2):308-309. PubMed ID: 29265463
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
    Ogata F; Kobayashi M; Akuta N; Osawa M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
    Oncology; 2017; 93(2):92-98. PubMed ID: 28448999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Did Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Really Improve the Survival of Patients with Hepatocellular Carcinoma?
    Lo GH
    Gastroenterology; 2020 May; 158(6):1843-1844. PubMed ID: 31953064
    [No Abstract]   [Full Text] [Related]  

  • 6. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis.
    Kao WY; Su CW
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1230-1231. PubMed ID: 29574869
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter?
    Ji F; Yeo YH; Wei MT; Wei B; Dang S; Li Z; Nguyen MH
    Hepatology; 2018 Mar; 67(3):1180-1182. PubMed ID: 29194694
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
    Tholey DM; Ahn J
    Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.
    Trotter JF
    Liver Transpl; 2017 Dec; 23(12):1593-1595. PubMed ID: 29024516
    [No Abstract]   [Full Text] [Related]  

  • 11. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
    Mehta N; Yao FY
    Liver Transpl; 2017 Dec; 23(12):1596-1600. PubMed ID: 29024442
    [No Abstract]   [Full Text] [Related]  

  • 12. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Piñero F; Silva M
    Liver Transpl; 2017 Dec; 23(12):1628-1629. PubMed ID: 29069533
    [No Abstract]   [Full Text] [Related]  

  • 13. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
    Jacobson IM; Lim JK; Fried MW
    Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
    Mantravadi S
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases.
    Tapia-Sosa R; Hernández-Cabral F; Gabutti A; Páez-Zayas VM; García-Juárez I
    Rev Gastroenterol Mex (Engl Ed); 2021; 86(2):197-199. PubMed ID: 33187768
    [No Abstract]   [Full Text] [Related]  

  • 19. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
    Blanco JR; Rivero-Juárez A
    Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
    [No Abstract]   [Full Text] [Related]  

  • 20. Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals.
    Soria A; Fabbiani M; Lapadula G; Gori A
    Hepatology; 2017 Sep; 66(3):992-994. PubMed ID: 28370176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.